Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.73 |
| ▸ | FADS1 | O60427 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.66 |
| ▸ | DNMT1 | P26358 | 4/20 | 0.63 |
| ▸ | DNMT3A | Q9Y6K1 | 3/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.63 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30420824 | 1.00 | ERBB2 (0.73) | ERBB2FADS1EGFRHTTALK | |
| SCHEMBL15923366 | 0.90 | ALK (0.72) | ERBB2FADS1EGFRHTTALK | |
| SCHEMBL31197381 | 0.90 | ALK (0.72) | ERBB2FADS1EGFRHTTALK | |
| SCHEMBL17194814 | 0.89 | MEN1 (0.62) | ERBB2FADS1EGFRHTTALK | |
| SCHEMBL5306062 | 0.89 | DNMT1 (0.68) | ERBB2FADS1EGFRHTTALK | |
| SCHEMBL6752938 | 0.88 | HTR1A (0.68) | ERBB2FADS1EGFRHTTDNMT1 | |
| SCHEMBL15673390 | 0.86 | ERBB2 (0.66) | ERBB2FADS1EGFRHTTDNMT1 | |
| SCHEMBL528895 | 0.86 | ERBB2 (0.61) | ERBB2FADS1EGFRHTTALK | |
| SCHEMBL15879950 | 0.86 | ERBB2 (0.66) | ERBB2FADS1EGFRHTTDNMT1 | |
| SCHEMBL12240670 | 0.86 | HTT (0.68) | ERBB2FADS1EGFRHTTDNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115466211-B | N-phenylquinoline-4-amine compound and application thereof | 中国人民解放军空军军医大学 | 2024-02-23 | — | — | CN | claimed |
| CN-115466211-A | N-phenylquinoline-4-amine compound and application thereof | 中国人民解放军空军军医大学 | 2022-12-13 | — | — | CN | claimed |
| EP-2678052-B1 | JAB1 BLOCKING COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | UNIV EMORY (US) | 2018-09-26 | — | — | EP | claimed |
| CN-107417735-A | New E GFR and DNA double target spot ruthenium class anti-tumor complex a kind of molecular design method | 浙江农林大学 | 2017-12-01 | — | — | CN | claimed |
| US-20150374694-A1 | TGF-BETA ENHANCING COMPOSITIONS FOR CARTILAGE REPAIR AND METHODS RELATED THERETO | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2015-12-31 | — | — | US | claimed |
| WO-2014130411-A9 | TGF-BETA ENHANCING COMPOSITIONS FOR CARTILAGE REPAIR AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-10-16 | — | — | WO | claimed |
| WO-2014130411-A1 | TGF-BETA ENHANCING COMPOSITIONS FOR CARTILAGE REPAIR AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-28 | — | — | WO | claimed |
| US-20130344165-A1 | JAB1 INHIBITORY COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-12-26 | — | — | US | claimed |
| WO-2012116137-A2 | JAB1 BLOCKING COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-08-30 | — | — | WO | claimed |
| US-20250255857-A1 | METHODS OF TREATING ANDROGEN RECEPTOR-INDEPENDENT PROSTATE CANCER | FOGHORN THERAPEUTICS INC. | 2025-08-14 | — | — | US | disclosed |
| US-12377194-B2 | JAB1 inhibitory compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4050005-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4399202-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Yukin Therapeutics (FR) | 2024-07-17 | — | — | EP | disclosed |
| CN-115466211-B | N-phenylquinoline-4-amine compound and application thereof | 中国人民解放军空军军医大学 | 2024-02-23 | — | — | CN | disclosed |
| WO-1989008105-A1 | 4-AMINO-3-ACYLQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-09-08 | — | — | WO | disclosed |
| WO-1989008104-A1 | 4-AMINO-3-ACYLQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-09-08 | — | — | WO | disclosed |
| WO-1989008112-A1 | THIENOPYRIDINES, PREPARATION, INTERMEDIATES AND PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-09-08 | — | — | WO | disclosed |
| EP-0331357-A1 | 4-Amino-3-acylquinoline derivatives and their use as inhibitors of gastric secretion | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-09-06 | — | — | EP | disclosed |
| EP-0330485-A1 | 4-Amino-3-acyl quinoline derivatives and their use as inhibitors of gastric acid secretion | SmithKline Beecham Intercredit B.V. (NL) | 1989-08-30 | — | — | EP | disclosed |
| CN-1034925-A | Quinoline, quinazoline and cinnoline | LILLY CO ELI (US) | 1989-08-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255857-A1 | METHODS OF TREATING ANDROGEN RECEPTOR-INDEPENDENT PROSTATE CANCER | AR, ESRRB, ESRRA | ERBB2 633/4885FADS1 1356/4885EGFR 289/4885 |
| US-20150374694-A1 | TGF-BETA ENHANCING COMPOSITIONS FOR CARTILAGE REPAIR AND METHODS RELATED THERETO | COL2A1, TGFB1, TGFBR1 | ERBB2 1537/4885FADS1 3487/4885EGFR 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.